Published in Drug Law Weekly, August 25th, 2009
"The combination of (188)Re-HEDP and capecitabine (Xeloda®) was tested in a clinical phase I study. Patients with hormone-refractory prostate cancer were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.